NanoString Technologies Highlights Advances in Precision

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NanoString Technologies Highlights Advances in Precision Oncology and Immunotherapy at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)

SEATTLE, June 02, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in precision oncology and immunotherapy using the nCounter® platform that will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).  

"For more than 50 years the American Society of Clinical Oncology has been pioneering cancer research and advancing the care of patients with cancer around the world," said Brad Gray, president and chief executive officer of NanoString Technologies. "We are proud to participate in the ASCO Annual Meeting and to have the opportunity to highlight the groundbreaking cancer research and diagnostic assays that are being enabled through the nCounter platform and our expanding portfolio of 3D Biology™ products."

More than 30 abstracts will be presented at the ASCO Annual Meeting, which is being held June 3rd through June 7th, 2016 in Chicago, Illinois, that demonstrate the value of the nCounter Platform.  In particular, several abstracts provide additional insights on the development and performance of NanoString’s investigational assays in development for immuno-oncology and lymphoma.

In immuno-oncology, NanoString and collaborators will present new details on nCounter-based assays under development for prediction of response to the checkpoint inhibitor pembrolizumab, including:

  • An interferon-gamma gene signature was shown to predict response more accurately than PD-L1 IHC in squamous cell carcinoma of the head and neck.  This research further demonstrates the power of gene expression profiling on the nCounter Analysis System as a biomarker in immuno-oncology. (Abstract #6010)
  • An interferon-gamma gene signature and an expanded immune gene signature predicted response in five tumor types from the basket trial KEYNOTE-28, underscoring the potentially broad applicability of gene signatures in assessing patient response (Abstract #1536).
  • Data on the development and analytical performance of an nCounter-based assay incorporating an immune-related gene signature to predict response to checkpoint inhibition in eleven different tumor types. The data show that this assay is robust and may be well-suited to clinical applications.  The signature is being evaluated as a predictive biomarker in multiple indications in several studies (Abstract #3034).

In lymphoma, NanoString and collaborators are presenting results generated using nCounter-based assays, including:

  • An update on the ongoing ROBUST trial, a global pivotal phase 3 trial evaluating the addition of lenalidomide to R-CHOP therapy in untreated ABC-type Diffuse Large B-cell Lymphoma (DLBCL) selected by NanoString’s investigational Cell-of-Origin assay.  The results show that real-time testing of Cell-of-Origin using nCounter is feasible in a multi-center, global study with turnaround time of less than 3 days, demonstrating that a decentralized gene expression test can be used to select patients for a clinical trial where rapid results are critical for enrollment (Abstract #7538).
  • Independent validation of the nCounter-based Cell-of-Origin assay through comparison to subtyping using DNA microarrays. The assay proved to be highly efficient and reliable in an independent series of samples evaluated by a team of researchers not involved in the development of the assay.  This research highlights the high concordance between the NanoString assay and the conventional microarray method as well as the robustness and ease of use of the assay, which can be successfully deployed in laboratories around the world (Abstract #7547).   

The 2016 ASCO abstracts describe research and clinical applications that underscore the diverse capabilities and robust performance of the nCounter platform. The studies cover a wide range of cancers, tissue types (FFPE, peripheral blood and urine), and treatment modalities.

At the 2016 ASCO Annual Meeting, NanoString will showcase its nCounter platform and 3D Biology capabilities at booth #8151.

Abstract #SummaryHyperlink
4525Subclassification and outcome prediction of patients with muscle invasive urothelial carcinoma (MIUC) treated by radical cystectomy (RC) with a NanoString based molecular screening.http://abstracts.asco.org/176/AbstView_176_167004.html

 
3034Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System.http://abstracts.asco.org/176/AbstView_176_168736.html

 
3008Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma.http://abstracts.asco.org/176/AbstView_176_170003.html

 
6056Immune-related gene expression signatures as predictive biomarkers for outcome after concurrent chemoradiation in patients with locally advanced oropharyngeal carcinomas.http://abstracts.asco.org/176/AbstView_176_169537.html

 
11522Derivation of gene expression classifiers for the non-invasive detection of bladder cancer in the hematuria and recurrence surveillance populations.http://abstracts.asco.org/176/AbstView_176_164671.html

 
e16014Multiplatform comprehensive kinase analysis of muscle-invasive bladder cancer (MIBC) to identify potentially actionable therapeutic targets.http://abstracts.asco.org/176/AbstView_176_169117.html

 
10561Patterns of PD-1, PD-L1 and PD-L2 expression in pediatric solid tumors.http://abstracts.asco.org/176/AbstView_176_168360.html

 
TPS3636The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer.http://abstracts.asco.org/176/AbstView_176_169577.html

 
3038Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types.http://abstracts.asco.org/176/AbstView_176_170034.html

 
7045Up-regulation of BAALC/MN1/MLLT11/EVI1 gene cluster in relation to MYC / BCL2 protein co-expression and poor overall survival in acute myeloid leukemia (AML).http://abstracts.asco.org/176/AbstView_176_171325.html

 
e20089Preliminary analysis of genomic profiling of small cell lung cancer in Chinese population revealed frequent PIK3CA hotspot mutations.http://abstracts.asco.org/176/AbstView_176_171299.html

 
e23235Analysis of RSPO gene expression in solid tumors.http://abstracts.asco.org/176/AbstView_176_170408.html

 
e14565Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).http://abstracts.asco.org/176/AbstView_176_170364.html

 
10509Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.http://abstracts.asco.org/176/AbstView_176_168561.html

 
e17103Genomic profiling of high-intermediate risk endometrial cancer to differentiate recurrence risk.http://abstracts.asco.org/176/AbstView_176_168355.html

 
3570Influence of mRNA expression of fibroblast growth factor 2 (FGF2) in colorectal cancer (CRC) cell lines and in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1).http://abstracts.asco.org/176/AbstView_176_164113.html

 
7510Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.http://abstracts.asco.org/176/AbstView_176_163878.html

 
TPS7575Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma.http://abstracts.asco.org/176/AbstView_176_163751.html

 
7538Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).http://abstracts.asco.org/176/AbstView_176_162475.html

 
TPS7577A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.http://abstracts.asco.org/176/AbstView_176_165061.html

 
6010Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).http://abstracts.asco.org/176/AbstView_176_165708.html

 
e20014The upregulation of FOXA2 transcription factor in RET rearranged lung adenocarcinoma.http://abstracts.asco.org/176/AbstView_176_162380.html

 
e16023PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC).http://abstracts.asco.org/176/AbstView_176_167453.html

 
543Prospective multicenter study of the impact of the Prosigna assay on adjuvant clinical decision-making in women with early stage breast cancer: which patients are the best candidates?http://abstracts.asco.org/176/AbstView_176_166948.html

 
7547Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.http://abstracts.asco.org/176/AbstView_176_165721.html

 
1536T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.http://abstracts.asco.org/176/AbstView_176_168432.html

 
3510Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07.http://abstracts.asco.org/176/AbstView_176_165798.html

 
1585Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes.http://abstracts.asco.org/176/AbstView_176_167604.html

 
575A retrospective study of SPAG5 expression and its clinical implications in >8,000 patients of ER positive (ER+) breast cancer (BC): Genomic, transcriptomic and protein analysis.http://abstracts.asco.org/176/AbstView_176_170849.html

 
569Outcomes of single versus double hormone receptor positive breast cancer.http://abstracts.asco.org/176/AbstView_176_169749.html

 
TPS623OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.http://abstracts.asco.org/176/AbstView_176_169580.html

 
e23143The genomic profile (GP) of early breast cancer (EBC): Daily practice analysis.http://abstracts.asco.org/176/AbstView_176_167027.html

 
555A test utilizing diagnostic and on-treatment biomarkers to improve prediction of response to endocrine therapy in breast cancer.http://abstracts.asco.org/176/AbstView_176_168226.html

 

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology, and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications dfarrell@nanostring.com Phone: 206-602-1768

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading